Skip to Content

Generic Tosymra Availability

Last updated on Sep 8, 2021.

Tosymra is a brand name of sumatriptan, approved by the FDA in the following formulation(s):

TOSYMRA (sumatriptan - spray;nasal)

  • Manufacturer: UPSHER SMITH LABS
    Approval date: January 25, 2019
    Strength(s): 10MG/SPRAY [RLD]

Has a generic version of Tosymra been approved?

No. There is currently no therapeutically equivalent version of Tosymra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tosymra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,603,305

    Patent expiration dates:

    • June 16, 2030
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Alkylglycoside compositions for drug administration
    Patent 8,268,791
    Issued: September 18, 2012
    Inventor(s): Maggio; Edward T.
    Assignee(s): Aegis Therapeutics, LLC.

    The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

    Patent expiration dates:

    • May 9, 2026
      ✓ 
      Drug product
  • Compositions for drug administration
    Patent 8,440,631
    Issued: May 14, 2013
    Assignee(s): Aegis Therapeutics, LLC

    The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

    Patent expiration dates:

    • May 9, 2026
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Formulations comprising triptan compounds
    Patent 9,211,282
    Issued: December 15, 2015
    Assignee(s): DR. REDDY'S LABORATORIES LTD.

    The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

    Patent expiration dates:

    • July 19, 2031
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Compositions for drug administration
    Patent 9,283,280
    Issued: March 15, 2016
    Assignee(s): Aegis Therapeutics, LLC

    The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.

    Patent expiration dates:

    • May 9, 2026
      ✓ 
      Drug product
  • Formulations comprising triptan compounds
    Patent 9,610,280
    Issued: April 4, 2017
    Assignee(s): DR. REDDY'S LABORATORIES LIMITED

    The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

    Patent expiration dates:

    • June 16, 2030
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE
      ✓ 
      Drug product
  • Formulations comprising triptan compounds
    Patent 9,974,770
    Issued: May 22, 2018
    Assignee(s): DR. REDDY'S LABORATORIES LTD.

    The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

    Patent expiration dates:

    • June 16, 2030
      ✓ 
      Patent use: ACUTE TREATMENT OF MIGRAINE
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.